Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Recro Pharma stock | $1.74

Learn how to easily invest in Recro Pharma stock.

Recro Pharma Inc is a drug manufacturers-specialty & generic business based in the US. Recro Pharma shares (REPH) are listed on the NASDAQ and all prices are listed in US Dollars. Recro Pharma employs 185 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Recro Pharma

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – REPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Recro Pharma stock price (NASDAQ: REPH)

Use our graph to track the performance of REPH stocks over time.

Recro Pharma shares at a glance

Information last updated 2021-10-23.
Latest market close$1.74
52-week range$1.49 - $5.29
50-day moving average $2.04
200-day moving average $2.27
Wall St. target price$5.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.67

Buy Recro Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Recro Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Recro Pharma price performance over time

Historical closes compared with the close of $1.74 from 2021-10-25

1 week (2021-10-20) 1.74
1 month (2021-09-27) -15.94%
3 months (2021-07-27) -3.33%
6 months (2021-04-27) -38.52%
1 year (2020-10-26) -5.95%
2 years (2019-10-25) -86.41%
3 years (2018-10-26) 6.57
5 years (2016-10-26) 7.15

Is Recro Pharma under- or over-valued?

Valuing Recro Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Recro Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Recro Pharma's EBITDA

Recro Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.2 million.

The EBITDA is a measure of a Recro Pharma's overall financial performance and is widely used to measure a its profitability.

Recro Pharma financials

Revenue TTM $64 million
Gross profit TTM $12.4 million
Return on assets TTM -3.15%
Return on equity TTM -351.19%
Profit margin -30.18%
Book value $0.57
Market capitalisation $83.9 million

TTM: trailing 12 months

Shorting Recro Pharma shares

There are currently 676,092 Recro Pharma shares held short by investors – that's known as Recro Pharma's "short interest". This figure is 22.6% up from 551,539 last month.

There are a few different ways that this level of interest in shorting Recro Pharma shares can be evaluated.

Recro Pharma's "short interest ratio" (SIR)

Recro Pharma's "short interest ratio" (SIR) is the quantity of Recro Pharma shares currently shorted divided by the average quantity of Recro Pharma shares traded daily (recently around 263070.81712062). Recro Pharma's SIR currently stands at 2.57. In other words for every 100,000 Recro Pharma shares traded daily on the market, roughly 2570 shares are currently held short.

However Recro Pharma's short interest can also be evaluated against the total number of Recro Pharma shares, or, against the total number of tradable Recro Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Recro Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Recro Pharma shares in existence, roughly 10 shares are currently held short) or 0.0156% of the tradable shares (for every 100,000 tradable Recro Pharma shares, roughly 16 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Recro Pharma.

Find out more about how you can short Recro Pharma stock.

Recro Pharma share dividends

We're not expecting Recro Pharma to pay a dividend over the next 12 months.

Have Recro Pharma's shares ever split?

Recro Pharma's shares were split on a 1115:1000 basis on 21 November 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1115 shares. This wouldn't directly have changed the overall worth of your Recro Pharma shares – just the quantity. However, indirectly, the new 10.3% lower share price could have impacted the market appetite for Recro Pharma shares which in turn could have impacted Recro Pharma's share price.

Recro Pharma share price volatility

Over the last 12 months, Recro Pharma's shares have ranged in value from as little as $1.49 up to $5.29. A popular way to gauge a stock's volatility is its "beta".

REPH.US volatility(beta: 1.18)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Recro Pharma's is 1.1757. This would suggest that Recro Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Recro Pharma overview

Recro Pharma, Inc. , a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.

Frequently asked questions

What percentage of Recro Pharma is owned by insiders or institutions?
Currently 7.127% of Recro Pharma shares are held by insiders and 70.831% by institutions.
How many people work for Recro Pharma?
Latest data suggests 185 work at Recro Pharma.
When does the fiscal year end for Recro Pharma?
Recro Pharma's fiscal year ends in December.
Where is Recro Pharma based?
Recro Pharma's address is: 1 E. Uwchlan Ave, Exton, PA, United States, 19341
What is Recro Pharma's ISIN number?
Recro Pharma's international securities identification number is: US75629F1093
What is Recro Pharma's CUSIP number?
Recro Pharma's Committee on Uniform Securities Identification Procedures number is: 75629F109

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site